Novo's Ozempic Soars As Focus Shifts To Oral Semaglutide

Sales of injectable semaglutide shored up Novo's second quarter, but all eyes are on the expected launch of an oral version in the third quarter.

Alarm
Novo Nordisk expecting a call soon from the FDA on oral semaglutide • Source: Shutterstock

Novo Nordisk AS has posted a healthy set of financials for the second quarter, helped by the strong launch of the injectable Ozempic (semaglutide) but all eyes are now on the third quarter and the expected US approval of the closely watched oral version of the once-weekly GLP-1 type 2 diabetes drug.

Ozempic Q2 sales came in at DK2.33bn ($349m), topping analyst consensus by 26%, and on a conference call, CEO Lars...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.